CinCor Pharma (CINC) Stock Analysis

What CinCor Pharma does

CinCor Pharma, Inc. is an emerging biopharmaceutical firm in the clinical development phase, dedicated to pioneering therapeutic solutions for cardiovascular and renal conditions. At the core of its pipeline is CIN-107, an investigational compound currently undergoing Phase II clinical trials for indications such as hypertension, primary aldosteronism, and various other cardio-renal disorders. Additionally, CIN-107 is in Phase I clinical evaluation for its potential in treating chronic kidney diseases. The company holds a significant licensing agreement with F. Hoffman-La Roche Ltd. and Hoffmann-La Roche Inc. Established in 2018, CinCor Pharma, Inc. maintains its principal operations in Boston, Massachusetts.

Key metrics

ETFs linked to CINC

Broad-market and Healthcare sector ETFs an investor holding CinCor Pharma is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how CINC fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for CinCor Pharma?

CinCor Pharma trades under the ticker CINC on NASDAQ.

Which exchange is CINC listed on?

CINC is listed on NASDAQ.

What sector does CinCor Pharma operate in?

CinCor Pharma is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze CINC in a portfolio?

PortView shows CINC's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.